title: Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists.
abstract: BACKGROUND
  Methotrexate is one the most commonly used systemic therapies for psoriasis. Despite its widespread use in psoriasis therapy, dermatologists' practice regarding the use of methotrexate has not been investigated on global scale.
  
  
  OBJECTIVE
  To evaluate the real life use of methotrexate for psoriasis treatment in the dermatological community worldwide.
  
  
  METHODS
  A questionnaire consisting of 41 questions was designed by the Psoriasis International Network (PIN). Questions focused on safety, dosing, administration, folic acid supplementation and combination therapy aspects of methotrexate use. The anonymous web-based survey was distributed to dermatologists by the national coordinators of PIN.
  
  
  RESULTS
  Between 2 April and 7 August 2012, 481 dermatologists from 63 countries completed the questionnaire. Most respondents were from European and South American countries, whereas the response rate from Central America and the Near East was lowest. The majority of responders were experienced dermatologists (86% had more than 5 years of experience in psoriasis treatment). Starting and maintenance doses of 10 mg of methotrexate or lower were reported by 67% and 42% of respondents respectively. Thirty-eight per cent of respondents stop treatment at a cumulative dose of 2 g, whereas 36% did not consider cumulative dose important in this respect. The primary mode of administration was oral, and the majority of respondents administer folic acid supplementation. Almost all respondents monitored full blood count, liver and renal function tests, whereas procollagen 3 amino terminal peptide measurement and transient elastography is used by only a minority of dermatologists. There were significant differences concerning the doses, routes of administration and safety monitoring among the clinical practices in different geographical locations.
  
  
  CONCLUSIONS
  Current clinical practice of methotrexate use in psoriasis is not uniform, depends on geographical location, and is not in full agreement with clinical guidelines.
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.|Department of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, Hungary.
authors.forename: R
authors.initials: R
authors.lastname: Gyulai
authors.affiliation: Department of Dermatology, Saint-Louis Hospital, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Bagot
authors.affiliation: Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester, UK.
authors.forename: C E M
authors.initials: CEM
authors.lastname: Griffiths
authors.affiliation: Department of Dermatology, University of Münster, Münster, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Luger
authors.affiliation: Department of Dermatology, Azienda Ospedaliera papa Giovanni XXIII, Bergamo, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Naldi
authors.affiliation: Department of Dermatology, Paul Sabatier University, CHU Larrey, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Paul
authors.affiliation: Department of Dermatology, Hospital de la Sanat Creu i Sant Pau, Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Puig
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
authors.forename: L
authors.initials: L
authors.lastname: Kemény
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000075202:Contraindications; D003880:Dermatology / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011565:Psoriasis / Q000188:drug therapy*; D011795:Surveys and Questionnaires
chemical_list: D008727:Methotrexate
references.citation: Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-1204.
references.citation: Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
references.citation: Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
references.citation: Flytstrom I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121.
references.citation: Weinstein GD, Frost P. Methotrexate for psoriasis, A new therapeutic schedule. Arch Dermatol 1971; 103: 33-38.
references.citation: Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-alpha. Clin Exp Rheumatol 2010; 28: S3-S8.
references.citation: Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
references.citation: Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
references.citation: Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol 2013; 38: 573-588.
references.citation: Ng LC, Lee YY, Lee CK, Wong SM. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. Int J Dermatol 2013; 52: 102-105.
references.citation: Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-1093.
references.citation: Montaudie H, Sbidian E, Paul C et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25: 12-18.
references.citation: Kirby B, Lyon CC, Griffiths CE, Chalmers RJ. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. Clin Exp Dermatol 2000; 25: 265-268.
references.citation: Barker J, Horn EJ, Lebwohl M et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011; 25: 758-764.